News

To characterise the different types of pulmonary hypertension (PH) among idiopathic inflammatory myopathy (IIM). A retrospective case series with assessment of PH by right heart catheterisation, ...
Panelists discuss how healthcare resource utilization is primarily driven by hospitalizations, medication costs, and ...
Merck's Winrevair gains FDA priority review for PAH label update after ZENITH trial shows major reduction in serious events and strong clinical impact.
PAH patients with cardiovascular disease risk had similar hospitalization and mortality rates as those without after a ...
Merck (NYSE:MRK) announced Wednesday that the U.S. Food and Drug Administration (FDA) granted priority review for its request ...
Seven cases of patent ductus arteriosus with pulmonary hypertension and reversal of the usual direction of flow are described. Breathing of a low oxygen mixture either initiated or increased the ...
Merck MRK announced that the phase III HYPERION study evaluating its pulmonary arterial hypertension (“PAH”) drug, Winrevair ...
The meta-analysis suggests that prophylactic indomethacin reduces the incidence of short-term morbidities such as later PDA (RR 0.29, CI 0.22 to 0.38), PDA ligation (RR 0.51, CI 0.33 to 0.71 ...
Transforming Pulmonary Arterial Hypertension Management: Bridging Clinical Practice, Innovative Therapies, and Economic Impact : Episode 7 Opinion Video June 19, 2025 ...
Group 4: CTEPH (chronic thromboembolic pulmonary hypertension)—In some patients, pulmonary embolism, or blood clots, in the lung’s arteries can form scar-like tissue, blocking or narrowing the ...
If you are diagnosed with pulmonary hypertension (PH) or your doctor suspects PH, it is important for you to see a specialist. Pulmonary arterial hypertension (PAH) is a rare, progressive lung disease ...
BMPER overexpression mitigated the vascular remodeling that characterizes pulmonary arterial hypertension (PAH), according to a preclinical study published in Cellular Signalling. In vivo and in ...